Research programme: isoflavonoid based cancer therapeutics - Noxopharm

Drug Profile

Research programme: isoflavonoid based cancer therapeutics - Noxopharm

Alternative Names: Idronoxil - Noxopharm; NOX 66

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Noxopharm
  • Class Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action Caspase stimulants; NADH oxidase inhibitors; Proto oncogene protein c-akt inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 Jan 2017 Royal North Shore Hospital plans a phase I trial for Prostate cancer (Metastatic disease, Second-line therapy or greater) in Australia (Suppository) (NCT03041285)
  • 26 Jun 2016 Preclinical trials in Cancer in Australia (unspecified route)
  • 26 Jun 2016 Noxopharm plans a phase I/IIa trial for Cancer, including Solid tumours (Monotherapy, Combination therapy, Metastatic disease, Second-line therapy or greater) (NCT02941523,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top